The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

Ross, D; Grigg, A; Schwarer, A; Arthur, C; Loftus, K; Mills, A; Filshie, R; Columbus, R; Reynolds, John; Seymour, J; Branford, S; Hughes, T

The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

journal contribution

posted on 2008-11-16, 00:00 authored by D Ross, A Grigg, A Schwarer, C Arthur, K Loftus, A Mills, R Filshie, R Columbus, John Reynolds, J Seymour, S Branford, T Hughes

The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

History

Journal

Blood

Volume

112

Issue

11

Season

Abstract # 1102

Pagination

1 - 1

Publisher

American Society of Hematology

Location

Washington, D. C.

ISSN

0006-4971

eISSN

1528-0020

Language

eng

Notes

Alternative source title : Blood (ASH Annual Meeting Abstracts); Chronic Myeloid Leukemia - Therapy Poster I presented at American Society of Hematology. Annual Meeting (50th : 2008 : San Francisco, California) held from 6 - 9 Dec. 2008

Publication classification

C2.1 Other contribution to refereed journal

Usage metrics

Keywords

chronic myeloid leukaemia patients imatinib complete molecular response (CMR)early relapse

The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

History

Journal

Volume

Issue

Season

Pagination

Publisher

Location

ISSN

eISSN

Language

Notes

Publication classification

Usage metrics

Categories

Keywords

Licence

Exports